SecBot SecBot

SOPH

SOPHiA GENETICS SA
Nasdaq· Services-Computer Processing & Data Preparation· Inc. V8· CIK 0001840706 Software & IT
$7.52 +0.17 (+2.31%)
Oct 26 4:00 PM ET · prev $7.35
Market cap
$600.2M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$9.00
+20% · range $7.00–14.00
Next earnings
Nov 3
in 8 days · EPS est. −$0.20
1 year
+79.0%
from $4.20 · Oct 27
30 days
−11.4%
from $8.49
52-week range
$3.89–8.92
−16% from high · low Nov 20
Avg volume 20D
610.7K
Oct 15 spike 1.75M
Short interest
🔒 Subscribers only
Insider net
−$2.6M
0 buyers · 10 sellers · since Jul 13
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
39
analyzed by SecBot
SecBot read MIXED 15 reports · 90 days
Balance 3 bearish · 1 bullish · 11 neutral oldest → newest, height = score
Avg score ·High conf. 11/15 ·Next Earnings date, Nov 3, 2026
Strongest BULLISH SOPHiA GENETICS reported Q2 2026 results with revenue of $23.3M (+27% YoY), beating the raised guidance…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S Jul 13 to Jul 27 4 days of insider sells: $365.7K by 3 insiders, avg $6.26
  • A Jul 20 HC Wainwright & Co. initiates
  • R Aug 4 SOPHiA GENETICS reported Q2 2026 results with revenue of $23.3M (+27…
  • S Aug 4 to Aug 27 12 days of insider sells: $1.2M by 6 insiders, avg $7.66
  • S Sep 8 to Sep 21 5 days of insider sells: $243.9K by 7 insiders, avg $7.84
  • S Oct 5 to Oct 13 3 days of insider sells: $795.5K by 9 insiders, avg $7.97

Signal stack

Where each data set points today.

  • InsidersBEARISH

    10 insiders sold $2.6M.

  • InstitutionsBULLISH

    Q2 2026: 9 added (1 new), 4 trimmed or exited. Largest new: Ameriprise Financial $12.8M.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Median target $9.00 (+20%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.190 → −$0.200 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    5% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.8M
in new stakes
FundMoveSharesValue
ROYCE & ASSOCIATES LPADD3,381,736$19.5M
PRINCIPAL FINANCIAL GROUP INCADD2,364,256$13.6M
AMERIPRISE FINANCIAL INCNEW2,216,752$12.8M
SEI INVESTMENTS COTRIM165,045$952.3K
FEDERATED HERMES, INC.TRIM141,992$819.3K
MILLENNIUM MANAGEMENT LLCDOUBLED138,409$798.6K
RENAISSANCE TECHNOLOGIES LLCADD113,300$653.7K
MORGAN STANLEYADD37,497$216.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is inside the target range. Median implies +20%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 5, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 5, 2026BTIG
MAINTAIN
MAINTAINBuy
Jul 20, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Jun 15, 2026BTIG
REITERATE
REITERATEBuy
May 6, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.6M
sold · 10 insiders
DateInsiderTypeValue
Oct 13, 2026
Xu Zhenyu
Chief Scientific Officer
SELL$28.7K
Oct 12, 2026
Camblong Jurgi
Executive Chairman
SELL$61.7K
Oct 12, 2026
Menu Philippe
Chief Medical Officer
SELL$36.3K
Oct 5, 2026
CARDOZA GEORGE
Chief Financial Officer
SELL$12.9K
Oct 5, 2026
Van Well Daan
Chief Legal Officer
SELL$50.1K
Oct 5, 2026
Menu Philippe
Chief Medical Officer
SELL$60.1K
Oct 5, 2026
Xu Zhenyu
Chief Scientific Officer
SELL$60.1K
Oct 5, 2026
Muken Ross
Chief Executive Officer
SELL$80.0K

Earnings setup

Estimates
Nov 3
reports in 8 days
−$0.20
EPS estimate, this quarter
−5%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.20-$0.20–-$0.20-5.3%$24.0M
Next Q-$0.16-$0.16–-$0.16-14.3%$26.3M
Current FY-$0.85-$0.85–-$0.85-9.0%$95.2M
Next FY-$0.50-$0.50–-$0.50+10.7%$118.7M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Three insiders at SOPHiA GENETICS, including the Executive Chairman and two C-suite officers, sold a combined $127K in…
CLUSTER — Impact 2/10
Oct 13, 2026 Insider
Xu Zhenyu sold 4,000 shares
Chief Scientific Officer @ $7.18 ($28.7K)
Oct 12, 2026 Insider
Camblong Jurgi sold 8,500 shares
Executive Chairman @ $7.26 ($61.7K)
Oct 12, 2026 Insider
Menu Philippe sold 5,000 shares
Chief Medical Officer @ $7.26 ($36.3K)
Oct 5, 2026 SEC
Director George Cardoza filed a Form 144 notice of intent to sell 1,592 shares of SOPHiA GENETICS common stock, with…
144 — Impact 2/10
Sep 16, 2026 SEC
Four SOPHiA GENETICS insiders, including the Executive Chairman and Chief Legal Officer, sold a total of $195K in…
CLUSTER — Impact 2/10
Aug 4, 2026 Earnings
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global
Jun 30, 2026 Inst.
ROYCE & ASSOCIATES LP — ADD
3,381,736 shares ($19.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
SOPH Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Aug 4, 2026
Earnings
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today…
Aug 4, 2026
Earnings date
SOPH Q2 2026 Earnings Scheduled — 2026-08-04
May 5, 2026
Earnings date
SOPH Q1 2026 Earnings Scheduled — 2026-05-05
Mar 3, 2026
Earnings date
SOPH Q4 2025 Earnings After Market Close — 2026-03-03

SecBot reports

39 filings · 2 bullish · 8 bearish · 1 mixed · 28 neutral
All SOPH filing & press-release reports (39)